| Emotional PMS symptoms | For PMS, in 32 women who completed the crossover study, emotional symptoms with 50 mg pyridoxine daily were 2.97 study-scale points lower than with placebo after adjustment for phase (p<0.05).2.97 points (SE 1.37), p<0.05; 32 completers | 2/4 LowConfidence is low: a randomised trial exists for the exact comparison. Double-blind crossover RCT; 32 of 63 completed it, only 5 dropouts replied to the letter, and completers had more pronounced symptoms than those who completed 4–6 months. The substantial, potentially non-random loss creates serious uncertainty; the authors accounted for phase and for 5 partial completers separately. Only 32 completers, difference 2.97 with SE 1.37 on a 0–63 range; the relatively large error compared with the estimate leaves uncertainty about direction and magnitude on replication. The original CI was not provided; the clinical significance of the magnitude is unknown. Independent replication of this exact outcome has not been established; publication bias remains unknown. This is an assessment of confidence in the comparative result, not of clinical significance or safety. | 11 trialPyridoxine (vitamin B6) and the premenstrual syndrome: a randomized crossover trial ↗ | Women aged 18–49 with moderate or marked premenstrual symptoms; 63 enrolled, 32 completed | - Pyridoxine (vitamin B6) and the premenstrual syndrome: a randomized crossover trial ↗
|
|---|
| Total anxiety score | In the high-dose B6 study, change in total anxiety score after about a month did not differ convincingly from placebo: time×group interaction p=0.140.SCAARED: 24.8→21.5 versus 25.1→23.9; interaction p=0.140 | 2/4 LowConfidence is low: a randomised trial exists for the exact comparison. Bottles were randomised by computer; they concealed the tablets, but the tablets differed in appearance. For a subjective outcome, possible unblinding and exclusions based on data availability raise serious concern; the B6 count is inconsistent: table 1 88, table 3 df87, text t(88), PICO retained n89. The analysis included approximately 88–89 versus 87, with SD of baseline and final scores approximately 12.7–14.6; the authors report a detectable effect of 0.30 at 80% power. A between-group CI was not provided, and small effects cannot be ruled out with these data; p=0.140 does not prove equivalence. Independent replication of this exact outcome has not been established; publication bias remains unknown. This is an assessment of confidence in the comparative result, not of clinical significance or safety. | 11 trialHigh-dose Vitamin B6 supplementation reduces anxiety and strengthens visual surround suppression ↗ | Young people in the anxiety study; analyzed B6 n=89, placebo n=87. | - High-dose Vitamin B6 supplementation reduces anxiety and strengthens visual surround suppression ↗
|
|---|
| Nausea in pregnancy | In pregnant women before 17 weeks, nausea over 5 days fell by 2.9 out of 10 points with 30 mg pyridoxine daily and 2.0 points with placebo; difference in changes 0.9 points (p=0.0008).VAS decrease 2.9±2.2 versus 2.0±2.7 out of 10; difference 0.9; p=0.0008 | 3/4 ModerateConfidence is moderate: a randomised trial exists for the exact comparison. Random number table, identical placebo, double blinding; 336 of 342 were analysed, with 2 and 4 dropouts. Allocation concealment and registration are not fully established, but serious risk is not demonstrated by the available data. 336 analysed, change 2.9±2.2 versus 2.0±2.7 on a 10-cm scale. Given the moderate number and variability substantially exceeding the difference of 0.9, both a small and a more meaningful difference are possible; the comparative CI and patient-importance threshold were not reported. The downgrade is based on size and variability, not only p. Independent replication of this exact outcome has not been established; publication bias remains unknown. This is an assessment of confidence in the comparative result, not of clinical significance or safety. | 11 trialPyridoxine for nausea and vomiting of pregnancy: a randomized, double-blind, placebo-controlled trial ↗ | Pregnant women with nausea before 17 weeks; 342 randomized, 336 analyzed | - Pyridoxine for nausea and vomiting of pregnancy: a randomized, double-blind, placebo-controlled trial ↗
|
|---|
| Vomiting episodes in pregnancy | In the same study, vomiting episodes over 5 days decreased by 1.22 daily versus 0.65 with placebo; the difference in the period average was not statistically significant (p=0.0552).1.22±2.0 versus 0.65±2.4 episodes daily; p=0.0552 | 3/4 ModerateConfidence is moderate: a randomised trial exists for the exact comparison. The same double-blind RCT methods and 6 dropouts out of 342; the analysis of episode counts was restricted to participants with vomiting at baseline. Selection by baseline status before treatment and relatively small attrition do not in themselves justify a serious downgrade. 112 versus 111, reduction of 1.22±2.0 versus 0.65±2.4 episodes per day: variability greatly exceeds the difference, and the range of plausible magnitudes includes important uncertainty about direction. p=0.0552 does not prove equivalence; no CI was provided. Independent replication of this exact outcome has not been established; publication bias remains unknown. This is an assessment of confidence in the comparative result, not of clinical significance or safety. | 11 trialPyridoxine for nausea and vomiting of pregnancy: a randomized, double-blind, placebo-controlled trial ↗ | Pregnant women vomiting at baseline; outcome table n=112 B6 and n=111 placebo | - Pyridoxine for nausea and vomiting of pregnancy: a randomized, double-blind, placebo-controlled trial ↗
|
|---|
| Vomiting after treatment | In the smaller pregnancy study, vomiting after three days occurred in 8 of 31 taking 75 mg pyridoxine daily and 15 of 28 on placebo.8/31 versus 15/28 vomiting after treatment | 2/4 LowConfidence is low: a randomised trial exists for the exact comparison. Double-blind RCT, but 59 of 74 completed it; reasons for dropout, distribution of dropouts and analysis of all randomised participants by group are unknown. Substantial attrition may change the observed comparison. Only the official abstract is available; the full article was not checked. 59 completers, 8/31 versus 15/28 with vomiting; few events and small groups permit a wide range of plausible magnitudes of the difference. No CI was provided or calculated. Independent replication of this exact outcome has not been established; publication bias remains unknown. This is an assessment of confidence in the comparative result, not of clinical significance or safety. | 11 trialVitamin B6 is effective therapy for nausea and vomiting of pregnancy: a randomized, double-blind placebo-controlled study ↗ | Pregnant women with nausea or vomiting; 74 randomized, 59 completed | - Vitamin B6 is effective therapy for nausea and vomiting of pregnancy: a randomized, double-blind placebo-controlled study ↗
|
|---|
| Stress: whole group | In adults with stress and low magnesium, adding 30 mg B6 to 300 mg magnesium daily showed no convincing advantage at 8 weeks: stress-score improvement difference 0.72 points (95% CI −1.15…2.59).0.72 points (95% CI −1.15…2.59); 44.9% versus 42.4% improvement from baseline | 2/4 LowConfidence is low: a randomised trial exists for the exact comparison. Centralised randomisation and investigator blinding; participants were not blinded when self-assessing stress using DASS, which may systematically affect the result. Difference 0.72 points, 95% CI −1.15 to 2.59; the interval permits both a small advantage for magnesium and an advantage for the supplement of up to 2.59 points. Against the 42-point scale and without an established threshold, practical significance and the possibility of a moderate difference remain unresolved; zero alone is not grounds for a downgrade. Independent replication of this exact outcome has not been established; publication bias remains unknown. This is an assessment of confidence in the comparative result, not of clinical significance or safety. | 11 trialSuperiority of magnesium and vitamin B6 over magnesium alone on severe stress in healthy adults with low magnesemia: A randomized, single-blind clinical trial ↗ | Healthy adults with stress and suboptimal magnesium; mITT n=264 | - Superiority of magnesium and vitamin B6 over magnesium alone on severe stress in healthy adults with low magnesemia: A randomized, single-blind clinical trial ↗
|
|---|
| Stress: high-stress subgroup | In the subgroup with high stress and low magnesium, magnesium plus B6 reduced stress score by 3.16 points more than magnesium alone over 8 weeks (95% CI 0.50–5.82).DASS-42 improvement difference 3.16 points; 95% CI 0.50–5.82; p=0.0203 | 2/4 LowConfidence is low: a randomised trial exists for the exact comparison. Unblinded participants assess subjective stress; the severe subgroup analysis was added after closure of the blinded database based on an observed interaction, and randomisation was not stratified by baseline stress severity. Together these constitute serious risk-of-bias concerns, not automatically two separate downgrades. Difference 3.16 points, 95% CI 0.50–5.82, n=162; the range spans a very small and a noticeably larger improvement on DASS, while the practical threshold is unknown. Excluding zero does not make the magnitude sufficiently precise. Independent replication of this exact outcome has not been established; publication bias remains unknown. This is an assessment of confidence in the comparative result, not of clinical significance or safety. | 11 trialSuperiority of magnesium and vitamin B6 over magnesium alone on severe stress in healthy adults with low magnesemia: A randomized, single-blind clinical trial ↗ | Subgroup of healthy adults with high stress and suboptimal magnesium; mITT n=162 | - Superiority of magnesium and vitamin B6 over magnesium alone on severe stress in healthy adults with low magnesemia: A randomized, single-blind clinical trial ↗
|
|---|